Royleanone

Royleanone

SCHEMBL21291506

CC(C)C1=C(O)C(=O)C2=C(CC[C@H]3C(C)(C)CCC[C@]23C)C1=O

nearest known ligand 0.44

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP3A4 P08684 4/20 0.44
▸ USP2 O75604 3/20 0.44
▸ TP53 P04637 3/20 0.44
▸ MAPT P10636 3/20 0.44
▸ CYP19A1 P11511 2/20 0.44
▸ KDM4E B2RXH2 2/20 0.44
▸ MEN1 O00255 2/20 0.44
▸ MAPK1 P28482 2/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ HSP90AA1 P07900 1/20 0.44
▸ EP300 Q09472 1/20 0.42
▸ FDPS P14324 6/20 0.38
▸ GGPS1 O95749 2/20 0.36
▸ BCL9 O00512 3/20 0.36
▸ CTNNB1 P35222 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ HPGD P15428 2/20 0.36
▸ PTGES O14684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ PNLIP P16233 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Royleanone SCHEMBL16006778 1.00 CYP3A4 (0.44) CYP3A4USP2TP53MAPTCYP19A1
SCHEMBL13423517 0.83 FDPS (0.50) CYP3A4USP2TP53MAPTCYP19A1
SCHEMBL21291505 0.79 EP300 (0.40) CYP3A4USP2TP53MAPTCYP19A1
SCHEMBL22861898 0.78 EP300 (0.42) CYP19A1EP300FDPSGGPS1
SCHEMBL22861899 0.78 EP300 (0.42) CYP19A1EP300FDPSGGPS1
Horminone SCHEMBL22861891 0.77 CYP19A1 (0.45) CYP3A4USP2TP53MAPTCYP19A1
Horminone SCHEMBL22861860 0.77 CYP19A1 (0.45) CYP3A4USP2TP53MAPTCYP19A1
SCHEMBL15732245 0.76 EP300 (0.46) CYP3A4USP2TP53MAPTCYP19A1
SCHEMBL30525549 0.74 FDPS (0.50) CYP3A4USP2TP53MAPTCYP19A1
SCHEMBL21291527 0.74 TP53 (0.39) CYP3A4USP2TP53MAPTCYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210000841-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2021-01-07 — — US disclosed
WO-2019158359-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS SOCIETE DES PRODUITS NESTLE S.A. (CH) 2019-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210000841-A1 COMPOUNDS THAT MODULATE VON WILLEBRAND FACTOR LEVELS AND THEIR USE IN THE TREATMENT OF BLOOD DISORDERS F5, F2, F3 CYP3A4 3823/4885USP2 4388/4885TP53 3589/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback